Page 50 - GALENIKA MEDICAL JOURNAL

11. Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular 27. Essa H, Wright DJ, Dobson R, Lip GYH. Chemotherapy-Induced
effects - UpToDate [Internet]. [cited 2023 Feb 17]. Available from: Arrhythmia - Underrecognized and Undertreated. Am J Med. 2021
https://www.uptodate.com/contents/toxicity-of-molecularly-targeted- Oct;134(10):1224-1231.e1.
antiangiogenic-agents-cardiovascular-effects
28. Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular
12. Cardiotoxicity of trastuzumab and other HER2-targeted agents - diseases in patients receiving small molecules with anti-vascular
UpToDate [Internet]. [cited 2023 Feb 17]. Available from: https://www. endothelial growth factor activity: A meta-analysis of approximately
uptodate.com/contents/cardiotoxicity-of-trastuzumab-and-other-her2- 29,000 cancer patients. Eur J Prev Cardiol. 2018 Mar;25(5):482-94.
targeted-agents
29. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ,
13. Cardiotoxicity of cancer chemotherapy agents other than Karumanchi SA, et al. Suppression of the nitric oxide pathway in
anthracyclines, HER2-targeted agents, and fluoropyrimidines - metastatic renal cell carcinoma patients receiving vascular endothelial
UpToDate [Internet]. [cited 2023 Feb 17]. Available from: https://www. growth factor-signaling inhibitors. Hypertension. 2010 Dec;56(6):1131-
uptodate.com/contents/cardiotoxicity-of-cancer-chemotherapy-agents- 6.
other-than-anthracyclines-her2-targeted-agents-and-fluoropyrimidines
30. Hatem R, Bebawi E, Schampaert E. Potential Sunitinib-Induced
14. Risk and prevention of anthracycline cardiotoxicity - UpToDate Coronary Artery and Aortic Dissections. Can J Cardiol. 2017
[Internet]. [cited 2023 Feb 17]. Available from: https://www.uptodate. Jun;33(6):830.e17-830.e18.
com/contents/risk-and-prevention-of-anthracycline-cardiotoxicity
31. Guyon J, Gouverneur A, Maumus-Robert S, Bérard X, Pariente A, Bikfalvi
15. Clinical manifestations, diagnosis, and treatment of anthracycline- A, et al. Association Between Antiangiogenic Drugs Used for Cancer
induced cardiotoxicity - UpToDate [Internet]. [cited 2023 Feb 17]. Treatment and Artery Dissections or Aneurysms. JAMA Oncol. 2021 May
Available from: https://www.uptodate.com/contents/clinical- 1;7(5):775-78.
manifestations-diagnosis-and-treatment-of-anthracycline-induced-
cardiotoxicity 32. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and
arterial thromboembolic events with the angiogenesis inhibitor
16. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients bevacizumab in cancer patients: a meta-analysis of randomized
treated with doxorubicin: a retrospective analysis of three trials. Cancer. controlled trials. Acta Oncol. 2010 Apr;49(3):287-97.
2003 Jun 1;97(11):2869-79.
33. Faheem B, Kania B, Ashkar H, Bondili L, Maroules M. 5-Fluorouracil-
17. Armstrong GT, Joshi VM, Ness KK, Marwick TH, Zhang N, Srivastava D, et related Cardiotoxicity with Coronary Vasospasms. J Community Hosp
al. Comprehensive Echocardiographic Detection of Treatment-Related Intern Med Perspect. 2022 Sep 9;12(5):71-4.
Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results
From the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015 Jun 34. Moghaddam ZK, Rostami M, Zeraatchi A, Abadi HF, Karamitanha
16;65(23):2511-22. F, Amirmoghaddami H. Evaluation Of 5-Fluorouracil-Induced
Cardiotoxicity: Role Of Cardiac Biomarkers. Exp Oncol. 2022
18. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, May;44(1):60-6.
et al. Axitinib versus sorafenib as second-line treatment for advanced
renal cell carcinoma: overall survival analysis and updated results from 35. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety
a randomised phase 3 trial. Lancet Oncol. 2013 May;14(6):552-62. R, Renée N. Dihydropyrimidine dehydrogenase deficiency and
fluorouracil-related toxicity. Br J Cancer. 1999 Feb;79(3-4):627-30.
19. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L,
et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. 36. Zhou H, Liu L, Ma X, Wang J, Yang J, Zhou X, et al. RIP1/RIP3/MLKL-
Lancet. 2007 Dec 15;370(9604):2011-9. mediated necroptosis contributes to vinblastine-induced myocardial
damage. Mol Cell Biochem. 2021 Feb;476(2):1233-43.
20. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al.
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. 37. Tebbutt NC, Murphy F, Zannino D, Wilson K, Cummins MM, Abdi
N Engl J Med. 2006 Dec 28;355(26):2733-43. E, et al; Australasian Gastro-Intestinal Trials Group. Risk of arterial
thromboembolic events in patients with advanced colorectal cancer
21. Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, et al. receiving bevacizumab. Ann Oncol. 2011 Aug;22(8):1834-8.
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in
patients with HER2-positive metastatic breast cancer in CLEOPATRA: 38. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous
a randomized, double-blind, placebo-controlled phase III study. thromboembolism with the angiogenesis inhibitor bevacizumab in
Oncologist. 2013;18(3):257-64. cancer patients: a meta-analysis. JAMA. 2008 Nov 19;300(19):2277-85.
22. Gan L, Liu D, Ma Y, Chen X, Dai A, Zhao S, et al. Cardiotoxicity associated 39. Cocco LD, Chiaparini AF, Saffi MAL, Leiria TLL. Global Longitudinal Strain
with immune checkpoint inhibitors: Current status and future for the Early Detection of Chemotherapy-Induced Cardiotoxicity: A
challenges. Front Pharmacol. 2022 Aug 30;13:962596. Systematic Review and Meta-analysis. Clin Oncol (R Coll Radiol). 2022
Aug;34(8):514-25.
23. Chen DY, Huang WK, Chien-Chia Wu V, Chang WC, Chen JS, Chuang CK,
et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer 40. Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M,
patients: A review when cardiology meets immuno-oncology. J Formos Lemieux J, et al; SUCCOUR Investigators. Strain-Guided Management
Med Assoc. 2020 Oct;119(10):1461-75. of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2021 Feb
2;77(4):392-401.
24. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling
LM, et al. Myocarditis in Patients Treated With Immune Checkpoint
Inhibitors. J Am Coll Cardiol. 2018 Apr 24;71(16):1755-64.
Konflikt interesa: Nema
25. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks
et al. Fulminant Myocarditis with Combination Immune Checkpoint Primljeno: 17. 03. 2023.
Blockade. N Engl J Med. 2016 Nov 3;375(18):1749-1755. Altan M, Toki Prihvaćeno: 18. 04. 2023.
MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, et al.
Immune Checkpoint Inhibitor–Associated Pericarditis. J Thorac Oncol. Onlajn: 01. 06. 2023.
2019 Jun 1;14(6):1102–8.
26. Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J,
Sinard JH, et al. Immune Checkpoint Inhibitor-Associated Pericarditis. J
Thorac Oncol. 2019 Jun;14(6):1102-8.

48 DOI: 10.5937/Galmed2306040B